title: [Pruritus in psoriasis : Profile and therapy].
abstract: Psoriasis is a common chronic inflammatory disease with an incidence of about 0.5-3 %. Previously psoriasis was not primarily regarded to be associated with pruritus; however, this perception has changed in recent years. Meanwhile data conclusively show that between 64 and 97 % of patients report about pruritus that can be severe in a number of cases. Apart from suffering from psoriasis, the presence of pruritus causes additional stress and leads to a significant impairment of health-related quality of life. Neurogenic inflammation at least in part contributes to the development of pruritus in psoriasis skin lesions. A number of neuropeptides including substance P and calcitonin gene related peptide can act as pro-inflammatory mediators. There is evidence for a dysbalance between κ‑ and µ‑opioid receptors in lesional skin favoring inflammation and pruritus. After clearing of psoriasis lesions, pruritus is relieved as well. Therefore, specific treatment of pruritus is not necessary in general. In cases where severe pruritus is a prominent symptom, targeted therapy with mirtazapin or doxepin or neuroleptic compounds such as pregabalin or gabapentin or drugs affecting the κ‑ und µ‑opioid receptor balance can be administered. Today the importance of pruritus as a prominent symptom of psoriasis lesions has been widely accepted. In recent and running clinical trials with new drugs, pruritus at baseline and the effect of these drugs on pruritus is always assessed. This awareness also fuels basic research about pruritus in psoriasis.
authors.affiliation: Klinik für Hautkrankheiten, Universitätsklinikum Münster, Von-Esmarch-Str. 58, 48149, Münster, Deutschland. Athanasios.Tsianakas@ukmuenster.de.
authors.forename: A
authors.initials: A
authors.lastname: Tsianakas
authors.affiliation: Psoriasis-Zentrum an der Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland.
authors.forename: U
authors.initials: U
authors.lastname: Mrowietz
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000982:Antipruritics / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D018836:Inflammation Mediators / Q000276:immunology; D058990:Molecular Targeted Therapy / Q000379:methods; D011537:Pruritus / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy*; D011565:Psoriasis / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy*; D012867:Skin / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000982:Antipruritics; D014150:Antipsychotic Agents; D018836:Inflammation Mediators
keywords: Antidepressants; Antipsoriatics; Neuroleptics; Quality of life; Skin diseases